[go: up one dir, main page]

CL2018003060A1 - Compuestos de pirimidina como inhibidores de la quinasa jak. - Google Patents

Compuestos de pirimidina como inhibidores de la quinasa jak.

Info

Publication number
CL2018003060A1
CL2018003060A1 CL2018003060A CL2018003060A CL2018003060A1 CL 2018003060 A1 CL2018003060 A1 CL 2018003060A1 CL 2018003060 A CL2018003060 A CL 2018003060A CL 2018003060 A CL2018003060 A CL 2018003060A CL 2018003060 A1 CL2018003060 A1 CL 2018003060A1
Authority
CL
Chile
Prior art keywords
inhibitors
compounds
pyrimidine compounds
jak kinase
intermediaries
Prior art date
Application number
CL2018003060A
Other languages
English (en)
Inventor
Ryan Hudson
Jennifer Kozak
Paul R Fatheree
Dante D Podesto
Melissa Fleury
Anne-Marie Beausoleil
Xiaojun Huang
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of CL2018003060A1 publication Critical patent/CL2018003060A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCIÓN PROVEE COMPUESTOS DE FÓRMULA (I), DONDE LAS VARIABLES SE DEFINEN EN LA MEMORIA DESCRIPTIVA, O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE LOS MISMOS, QUE SON INHIBIDORES DE LAS QUINASAS JAK. LA INVENCIÓN TAMBIÉN PROVEE COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN TALES COMPUESTOS, MÉTODOS DE USO DE TALES COMPUESTOS PARA TRATAR ENFERMEDADES GASTROINTESTINALES Y OTRAS ENFERMEDADES INFLAMATORIAS, Y PROCESOS E INTERMEDIARIOS ÚTILES PARA PREPARAR TALES COMPUESTOS.
CL2018003060A 2016-04-28 2018-10-26 Compuestos de pirimidina como inhibidores de la quinasa jak. CL2018003060A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662328737P 2016-04-28 2016-04-28

Publications (1)

Publication Number Publication Date
CL2018003060A1 true CL2018003060A1 (es) 2018-12-14

Family

ID=58672793

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003060A CL2018003060A1 (es) 2016-04-28 2018-10-26 Compuestos de pirimidina como inhibidores de la quinasa jak.

Country Status (20)

Country Link
US (3) US10028960B2 (es)
EP (1) EP3433253B1 (es)
JP (1) JP6881879B2 (es)
KR (1) KR102244257B1 (es)
CN (1) CN109071529B (es)
AU (1) AU2017258186B2 (es)
BR (1) BR112018072168A2 (es)
CA (1) CA3020506A1 (es)
CL (1) CL2018003060A1 (es)
CO (1) CO2018011408A2 (es)
DK (1) DK3433253T3 (es)
EA (1) EA035226B1 (es)
ES (1) ES2779880T3 (es)
IL (1) IL262386B (es)
MX (1) MX377180B (es)
PT (1) PT3433253T (es)
SG (1) SG11201809342YA (es)
TW (1) TWI726094B (es)
WO (1) WO2017189822A1 (es)
ZA (1) ZA201807179B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016267141B2 (en) 2015-05-28 2020-04-16 Theravance Biopharma R&D Ip, Llc Naphthyridine compounds as jak kinase inhibitors
EP3371184A1 (en) 2015-11-03 2018-09-12 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
EP3371185B1 (en) 2015-11-03 2020-09-30 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
CA3020506A1 (en) * 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors
MD3672965T2 (ro) 2017-10-27 2022-12-31 Theravance Biopharma R&D Ip Llc Compusi ai pirimidinei ca inhibitori ai kinazei JAK
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
TWI740288B (zh) * 2018-11-27 2021-09-21 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
WO2020108613A1 (zh) * 2018-11-30 2020-06-04 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
JP7482152B2 (ja) 2019-04-24 2024-05-13 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 皮膚疾患の処置のためのピリミジンｊａｋ阻害剤 発明の背景
PL3958969T3 (pl) * 2019-04-24 2024-05-20 Theravance Biopharma R&D Ip, Llc Estrowe i węglanowe związki pirymidynowe jako inhibitory kinaz
CN115867272A (zh) * 2020-05-14 2023-03-28 施万生物制药研发Ip有限责任公司 肠道选择性jak3抑制剂的给药
CN116390922A (zh) * 2020-10-21 2023-07-04 南京明德新药研发有限公司 硒杂环类化合物及其应用
WO2023011359A1 (zh) * 2021-08-05 2023-02-09 南京明德新药研发有限公司 桥环类化合物及其应用
CN113883920B (zh) * 2021-10-25 2024-01-23 安徽华铂再生资源科技有限公司 一种降低空分装置空冷塔出口温度的方法
WO2023202706A1 (zh) * 2022-04-21 2023-10-26 南京明德新药研发有限公司 硒杂环类化合物的盐型和晶型及其应用
WO2025040148A1 (zh) * 2023-08-22 2025-02-27 北京普祺医药科技股份有限公司 一种用于jak抑制剂的外用凝胶及其用途
WO2025059417A1 (en) * 2023-09-15 2025-03-20 Morphic Therapeutic, Inc. INHIBITING HUMAN INTEGRIN α4β7

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
ATE519759T1 (de) * 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
AU2006315334B2 (en) 2005-11-16 2011-05-19 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
KR20090024270A (ko) 2006-06-30 2009-03-06 아스트라제네카 아베 암 치료에 유용한 피리미딘 유도체
EP2043651A2 (en) 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
BR112014015549A8 (pt) 2011-12-22 2017-07-04 Hoffmann La Roche composto, método de inibição da atividade pak1, método para o tratamento, processo, composição, utilização de um composto e invenção
WO2015094803A1 (en) * 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (es) * 2014-08-21 2018-03-31
AU2016267141B2 (en) 2015-05-28 2020-04-16 Theravance Biopharma R&D Ip, Llc Naphthyridine compounds as jak kinase inhibitors
CA3020506A1 (en) * 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors

Also Published As

Publication number Publication date
IL262386A (en) 2018-11-29
US20200046709A1 (en) 2020-02-13
MX377180B (es) 2025-03-07
AU2017258186B2 (en) 2020-09-17
EA035226B1 (ru) 2020-05-19
CN109071529B (zh) 2021-08-06
MX2018013191A (es) 2019-02-13
CA3020506A1 (en) 2017-11-02
EA201892436A1 (ru) 2019-04-30
PT3433253T (pt) 2020-04-30
US10028960B2 (en) 2018-07-24
BR112018072168A2 (pt) 2019-02-12
TW201739747A (zh) 2017-11-16
US20180303836A1 (en) 2018-10-25
US11110095B2 (en) 2021-09-07
EP3433253B1 (en) 2020-02-12
EP3433253A1 (en) 2019-01-30
IL262386B (en) 2021-08-31
TWI726094B (zh) 2021-05-01
US10485803B2 (en) 2019-11-26
ZA201807179B (en) 2019-08-28
CO2018011408A2 (es) 2018-11-13
AU2017258186A1 (en) 2018-11-15
US20170312280A1 (en) 2017-11-02
JP2019514903A (ja) 2019-06-06
DK3433253T3 (da) 2020-04-06
CN109071529A (zh) 2018-12-21
KR20190002591A (ko) 2019-01-08
ES2779880T3 (es) 2020-08-20
JP6881879B2 (ja) 2021-06-02
KR102244257B1 (ko) 2021-04-26
WO2017189822A1 (en) 2017-11-02
SG11201809342YA (en) 2018-11-29

Similar Documents

Publication Publication Date Title
CL2018003060A1 (es) Compuestos de pirimidina como inhibidores de la quinasa jak.
CL2017002994A1 (es) Compuestos de naftiridina como inhibidores de la quinasa jak
CL2020000283A1 (es) Compuestos bicíclicos de pirazol y triazolo como inhibidores de las cinasas jak.
CL2018001145A1 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
ECSP19003773A (es) Compuestos heterocíclicos como inmunomoduladores
CL2017000712A1 (es) Pirimidinonas como inhibidores del factor xia
EA202090291A3 (ru) Производные бипиразола в качестве ингибиторов jak
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX2020011558A (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.
MX2018007774A (es) Compuestos heterociclicos como inmunomoduladores.
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
CR20170309A (es) Pirazolo [1,5-a] pirazinas 4,6-sustituidas como inhibidores de janus cinasas
MX2016010571A (es) Pirazolil-ureas como inhibidores de quinasas.
EA201890827A1 (ru) Конденсированные производные пиразола в качестве ингибиторов киназы
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
CL2018000611A1 (es) Sales de un inhibidor de pim quinasa
MX374555B (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
EA201600002A1 (ru) Производные пролекарства замещенных триазолопиридинов
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
EA202192822A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores